Significance of localized expression of full-length growth differentiation factor-15 in cachexia of advanced non-small cell lung cancer

[1]  Jingjing Deng,et al.  Value of Growth/Differentiation Factor 15 in Diagnosis and the Evaluation of Chemotherapeutic Response in Lung Cancer. , 2021, Clinical therapeutics.

[2]  Qian Zhang,et al.  Serum macrophage inhibitory cytokine‐1 as a clinical marker for non–small cell lung cancer , 2021, Journal of cellular and molecular medicine.

[3]  C. Catalano,et al.  Association between Growth Differentiation Factor-15 (GDF-15) Serum Levels, Anorexia and Low Muscle Mass among Cancer Patients , 2020, Cancers.

[4]  Ludger J. E. Goeminne,et al.  Growth differentiation factor 15 protects against the aging‐mediated systemic inflammatory response in humans and mice , 2020, Aging cell.

[5]  Subhash D. Katewa,et al.  Antibody-mediated inhibition of GDF15–GFRAL activity reverses cancer cachexia in mice , 2020, Nature Medicine.

[6]  Subhash D. Katewa,et al.  Antibody-mediated inhibition of GDF15–GFRAL activity reverses cancer cachexia in mice , 2020, Nature Medicine.

[7]  K. Brunt,et al.  Serum GDF15, a Promising Biomarker in Obese Patients Undergoing Heart Surgery , 2020, Frontiers in Cardiovascular Medicine.

[8]  V. W. Tsai,et al.  Growth differentiation factor-15 slows the growth of murine prostate cancer by stimulating tumor immunity , 2020, PloS one.

[9]  W. Fridman,et al.  Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint , 2020, Frontiers in Immunology.

[10]  C. Duan,et al.  Extensive serum biomarker analysis in patients with non-small-cell lung carcinoma. , 2020, Cytokine.

[11]  A. Sainsbury,et al.  The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases. , 2018, Cell metabolism.

[12]  Jie Tang,et al.  Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15 , 2017, Nature.

[13]  Søren B. Padkjær,et al.  GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand , 2017, Nature Medicine.

[14]  R. Gomis,et al.  TGF-β Family Signaling in Tumor Suppression and Cancer Progression. , 2017, Cold Spring Harbor perspectives in biology.

[15]  T. Mitsudomi,et al.  Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  S. Baek,et al.  The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. , 2013, Biochemical pharmacology.

[17]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[18]  A. Kozubík,et al.  Growth/differentiation factor-15: prostate cancer suppressor or promoter? , 2012, Prostate Cancer and Prostatic Diseases.

[19]  Paula Ravasco,et al.  Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.

[20]  L. Påhlman,et al.  Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer , 2011, British Journal of Cancer.

[21]  B. Davidson,et al.  Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. , 2010, Gynecologic oncology.

[22]  P. Ponikowski,et al.  Cachexia: a new definition. , 2008, Clinical nutrition.

[23]  Seong-ho Lee,et al.  Identification of Nonsteroidal Anti-inflammatory Drug-activated Gene (NAG-1) as a Novel Downstream Target of Phosphatidylinositol 3-Kinase/AKT/GSK-3β Pathway* , 2004, Journal of Biological Chemistry.

[24]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[25]  raina. chandler,et al.  Supportive Care in Cancer , 2003, Der Onkologe.